Compare AQMS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | CLRB |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 12.8M |
| IPO Year | 2015 | N/A |
| Metric | AQMS | CLRB |
|---|---|---|
| Price | $6.48 | $3.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 161.6K | 52.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.37 | $2.71 |
| 52 Week High | $39.40 | $20.60 |
| Indicator | AQMS | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 49.65 |
| Support Level | $6.93 | $3.30 |
| Resistance Level | $7.61 | $3.15 |
| Average True Range (ATR) | 0.59 | 0.28 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 0.00 | 65.32 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.